C.Q. Pharmaceutical Holding Co Ltd

C.Q. Pharmaceutical operates with a capital structure that is heavily leveraged, as evidenced by a debt-to-equity ratio of 2.14, which is significantly higher than the typical median for the pharmaceutical industry. The company's liquidity position is moderate, with a current ratio of 1.22, indicating that it has just enough current assets to cover its short-term liabilities. However, the company's free cash flow is negative at -191.1 million CNY, and capital expenditures are also negative at -299.5 million CNY, suggesting that the company is investing in its operations but is not generating sufficient cash to fund these investments internally. Profitability metrics for C.Q. Pharmaceutical are weak compared to industry benchmarks. The company's return on equity (ROE) is 3.35%, and its return on assets (ROA) is 0.58%, both of which are below the industry median for pharmaceutical firms. Gross profit of 5.85 billion CNY and operating income of 682.9 million CNY indicate that the company is generating some level of profitability, but the net income of 386.7 million CNY is relatively low given the company's asset base. The company's revenue is concentrated in a single geographic market, with the majority of its 82.45 billion CNY in revenue derived from domestic operations. There is no indication of significant international revenue or diversification across product lines. This concentration increases the company's exposure to domestic economic and regulatory risks. Looking ahead, the company's growth trajectory appears to be modest. Analysts have estimated a mean EPS of 0.33 CNY for the upcoming period, compared to the last actual EPS of 0.22 CNY. This suggests a potential increase in earnings per share, but the magnitude is relatively small. The company's revenue history does not show a strong growth trend, and there are no significant new product launches or market expansions that would indicate a substantial increase in revenue in the near term. The company faces several risk factors, including a high debt load and negative free cash flow, which could limit its ability to invest in growth opportunities or withstand economic downturns. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the key flag of negative net cash after subtracting total debt is a concern. The company has not issued new shares recently, and there is no indication of dilution pressure in the near term. Recent events and filings do not highlight any major changes in the company's operations or strategy. The company's 10-K filing does not mention any significant new initiatives or challenges, and there are no recent earnings call transcripts that provide additional insight into the company's future plans. The lack of detailed information makes it difficult to assess the company's long-term prospects.